Copy For Citation
Tanyeri,Tanyeri P., Buyukokuroglu M. E., Mutlu O., Ulak G., Akar F., Celikyurt I. K., ...More
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol.138, pp.142-147, 2015 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
138
-
Publication Date:
2015
-
Doi Number:
10.1016/j.pbb.2015.09.014
-
Journal Name:
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Page Numbers:
pp.142-147
-
Keywords:
Ziprasidone, SCH23390, SB277011, Cognition, Morris water maze, MK-801, Mice, COGNITIVE IMPAIRMENT, RECEPTOR ANTAGONIST, CHRONIC NICOTINE, NMDA RECEPTOR, SCHIZOPHRENIA, RATS, DIZOCILPINE, GLUTAMATE, PERFORMANCE, DEFICITS
-
Kocaeli University Affiliated:
Yes
Abstract
Introduction: Patients with schizophrenia have cognitive dysfunctions: positive psychotic symptoms are the primary purposes for schizophrenia treatment Improvements in cognitive function should be a characteristic of all newly developed drugs for the treatment of schizophrenia with dementia. Thus, we investigated the effects of the second-generation antipsychotic ziprasidone, dopamine D1 antagonist SCH-23390 and dopamine D3 antagonist SB-277011 on spatial learning and memory.